Valuation: United Therapeutics Corporation

Market Cap 23.76B 21.15B 19.6B 17.76B 33.37B 2,251B 33.93B 235B 92.38B 1,178B 89.11B 87.26B 3,757B P/E 2026 *
20.8x
P/E 2027 * 17.5x
Enterprise Value 21.05B 18.74B 17.36B 15.73B 29.57B 1,994B 30.07B 208B 81.85B 1,043B 78.95B 77.31B 3,329B EV / Sales 2026 *
6.59x
EV / Sales 2027 * 5.48x
Free-Float
53.72%
Yield 2026 *
-
Yield 2027 * -
1 day+0.64%
1 week+3.33%
Current month+2.98%
1 month+13.17%
3 months+4.14%
6 months-2.69%
Current year+14.53%
1 week 530.18
Extreme 530.1825
564.97
1 month 468.97
Extreme 468.97
585.79
Current year 455.63
Extreme 455.63
609.35
1 year 409.07
Extreme 409.07
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 25/06/1996
President 54 25/06/2016
Director of Finance/CFO 58 12/03/2015
Director TitleAgeSince
Director/Board Member 78 31/12/2001
Chairman 71 25/06/1996
Director/Board Member 92 31/12/2001
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Exercice

Chief Executive Officer

28,500 0.0664%
15/10/26 Exercice

General Counsel

24,900 0.0581%
14/10/26 Exercice

Chief Executive Officer

28,500 0.0664%
Change 5-day change 1-year change 3-year change Capi.($)
+0.54%+3.33%+32.09%+148.99% 23.76B
-1.11%+5.39%+59.32%+120.91% 1,144B
-1.50%+0.76%+33.33%+68.99% 625B
-1.06%+0.92%+23.64%+97.67% 511B
+0.32%+5.53%+39.39%+64.77% 377B
+0.29%+1.06%+69.97%+44.10% 366B
+0.22%+3.34%+21.23%+50.01% 291B
-0.01%+2.86%+1.43%+25.27% 262B
-0.43%+2.71%+45.34%+60.29% 237B
-2.33%+0.38%+24.21%+98.71% 194B
Average -0.59%+5.87%+34.99%+77.97% 403.17B
Weighted average by Cap. -0.85%+6.88%+40.69%+81.88%

Financials

2026 *2027 *
Net sales 3.2B 2.84B 2.64B 2.39B 4.49B 303B 4.57B 31.63B 12.43B 158B 11.99B 11.74B 505B 3.64B 3.24B 3B 2.72B 5.11B 345B 5.2B 36.03B 14.15B 180B 13.65B 13.37B 576B
Net income 1.22B 1.08B 1B 909M 1.71B 115B 1.74B 12.03B 4.73B 60.27B 4.56B 4.47B 192B 1.45B 1.29B 1.19B 1.08B 2.03B 137B 2.07B 14.32B 5.62B 71.7B 5.43B 5.31B 229B
Net Debt -2.71B -2.41B -2.23B -2.02B -3.8B -257B -3.87B -26.8B -10.53B -134B -10.16B -9.95B -428B -3.81B -3.4B -3.15B -2.85B -5.36B -361B -5.45B -37.76B -14.83B -189B -14.31B -14.01B -603B
Projected Income Statement - Annual - United Therapeutics Corporation
Logo United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.
Employees
1,400
Date Price Change Volume
21/10/26 US$558.11 +0.76% 15,351
20/10/26 US$553.88 +1.98% 443,279
19/10/26 US$543.15 +1.88% 498,297
16/10/26 US$533.12 -1.55% 668,250
15/10/26 US$541.51 +0.27% 545,400
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - United Therapeutics Corporation
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
553.88USD
Average target price
662.07USD
Spread / Average Target
+19.53%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - United Therapeutics Corporation
  1. Stock Market
  2. Stocks
  3. UTHR Stock